— Know what they know.
Not Investment Advice

SXTP NASDAQ

60 Degrees Pharmaceuticals, Inc.
1W: -6.0% 1M: -23.4% 3M: -54.4% YTD: -31.6% 1Y: -42.9%
$1.40
-0.01 (-0.71%)
After Hours: $1.38 (-0.02, -1.43%)
Weekly Expected Move ±7.3%
$1 $1 $1 $1 $2
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 39 · $1.1M mcap · 781119 float · 152.85% daily turnover · Short 46% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.1M
52W Range1.29-14.68
Volume54,976
Avg Volume1,193,906
Beta2.70
Dividend
Analyst Ratings
2 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOGeoffrey Stuart Dow
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-12
1025 Connecticut Avenue NW
Washington, DC 20036
US
202 327 5422
About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

Recent Insider Trades

NameTypeSharesPriceDate
Francois Eric 0 2026-05-13
DOW GEOFFREY S P-Purchase 9,670 $0.80 2025-12-15
DOW GEOFFREY S P-Purchase 3,613 $0.92 2025-12-11
DOW GEOFFREY S P-Purchase 9,350 $0.95 2025-12-10
DOW GEOFFREY S A-Award 7,201 $1.39 2025-09-12

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms